Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Accumulated Expenses (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Accumulated Expenses for 6 consecutive years, with $13.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 56.68% to $13.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.2 million, a 56.68% decrease, with the full-year FY2025 number at $13.2 million, down 56.68% from a year prior.
  • Accumulated Expenses was $13.2 million for Q4 2025 at Lexicon Pharmaceuticals, down from $13.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $30.4 million in Q4 2024 to a low of $10.1 million in Q1 2023.
  • A 3-year average of $16.5 million and a median of $15.5 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 77.46% in 2024, then crashed 56.68% in 2025.
  • Lexicon Pharmaceuticals' Accumulated Expenses stood at $17.2 million in 2023, then soared by 77.46% to $30.4 million in 2024, then plummeted by 56.68% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Accumulated Expenses are $13.2 million (Q4 2025), $13.6 million (Q3 2025), and $11.5 million (Q2 2025).